Ocuphire Pharma Says New OPGx-LCA5 Phase 1/2 6-Month Data Demonstrate Safety And Visual Improvement In Early Onset Retinal Degeneration; Company Will Seek A Strategic Partner To Continue Development Of APX3330, An Oral Small-Molecule Inhibitor Of...
Ocuphire Pharma Says New OPGx-LCA5 Phase 1/2 6-Month Data Demonstrate Safety And Visual Improvement In Early Onset Retinal Degeneration; Company Will Seek A Strategic Partner To Continue Development Of APX3330, An Oral Small-Molecule Inhibitor Of...
Ocuphire Pharma Says New OPGx-LCA5 Phase 1/2 6-Month Data Demonstrate Safety And Visual Improvement In Early Onset Retinal Degeneration; Company Will Seek A Strategic Partner To Continue Development Of APX3330, An Oral Small-Molecule Inhibitor Of Ref-1 For The Treatment Of Non-Proliferative Diabetic Retinopathy; Projected Cash Runway Extended Into 2026
ocuphire pharma表示，新的OPGx-LCA5 1/2期6個月數據表明在早發性視網膜變性中安全性和視覺改善；公司將尋求戰略合作伙伴繼續開發用於治療非增殖性糖尿病視網膜病變的APX3330，一種口服小分子Ref-1抑制劑；預計現金儲備將延至2026年
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations
收購將打造一個專注於罕見遺傳性視網膜變性基因治療的領先臨床階段公司
New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration
新的OPGx-LCA5 1/2期6個月數據表明在早發性視網膜退變中的安全性和視覺改善
Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025
預計2025年下半年將發佈LCA5兒童患者和BEST1患者的額外臨床數據
LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025
LYNX-2第3期試驗，針對光線暗淡中有障礙的患者使用0.75%氯胺酮眼用溶液，將於2025年第1季度發佈頭等數據
VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025
VEGA-3第3期試驗，針對老視症使用0.75%氯胺酮眼用溶液，將於2025年上半年發佈頭等數據
Company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy
公司將尋求戰略合作伙伴繼續開發APX3330，一種口服小分子Ref-1抑制劑，用於治療非增殖性糖尿病視網膜病變
Projected cash runway extended into 2026
預計現金儲備將延至2026年
Conference call to discuss the acquisition to take place at 4:30 p.m. ET today
討論收購事宜的電話會議將於今天下午4:30點進行。
FARMINGTON HILLS, Mich., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, today announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs). The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs. In connection with the merger, the combined company will be renamed Opus Genetics, Inc., effective October 23, 2024, and will trade on Nasdaq under the ticker symbol "IRD" effective October 24, 2024.
密歇根州法明頓希爾斯，2024年10月22日（環球新聞社）—ocuphire pharma公司（納斯達克股票代碼: OCUP），一家專注於開發和商業化治療視網膜和屈光眼疾患患者的療法的臨床階段眼科生物製藥公司，今天宣佈全股票收購Opus Genetics公司。該公司是一個致力於成爲遺傳性視網膜疾病（IRDs）的臨床階段基因療法公司。這一合併將打造一個變革性的生物技術公司，致力於成爲IRDs治療基因療法開發領域的領導者。與此次合併相關，合併後的公司將於2024年10月23日更名爲Opus Genetics公司，自2024年10月24日起將在納斯達克交易，股票代碼爲"IRD"。
